Review of Important Items from Sept 17-30
Here are a few of the important articles from the last couple of weeks.
Glaxo set to axe staff as crisis hits drug - Telegraph
Generic Biotech Drugs Won’t Be in U.S. Legislation Bloomberg.com: News
The Scientist : New patent rules hurt biotech?
Chemical & Engineering News: Government & Policy - Patent Reform Inches Ahead
AstraZeneca to outsource manufacturing - Times Online
AstraZeneca To Outsource Drug Manufacturing - Contract Pharma
StockHouse.com : Encysive Pharmaceuticals Receives Written Response From FDA On
Cephalon warns over pain drug deaths| Reuters
PharmaLive: Adverse Drug Events Reported to FDA Appear to Have Increased Markedly
Sanofi-Aventis Developing New Drugs: Financial News - Yahoo!
Finance
House Passes Bill to Improve Drug Safety: Financial News - Yahoo!
Finance
Senate OKs FDA drug safety bill - washingtonpost.com
Many drugs slip through regulatory ‘black hole’ - CNN.com
Bristol-Myers to buy partner Adnexus for $430 million”>SignOnSanDiego.com >
Warning issued on Cephalon painkiller | Philadelphia Inquirer | 09/27/2007
My overall observations is that there are many factors influencing the pharma industry today and these are not likely to less anytime in the near future. It would be nice to see more positive articles but those seem to be hard to come by in the current environment.
Technorati Tags: Adnexus, AstraZeneca, Bristol-Myers Squibb, Cephalon, Encysive, FDA, Glaxo, GlaxoSmithKline, Sanofi-Aventis
Related Posts:
Bookmark it with:
| 
del.icio.us
| 
Digg it
| 
Furl
| 
Simpy
| 
Spurl
| 
My Yahoo!
|
